Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease
(GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell
transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high
risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)